Last updated on November 2019

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Brief description of study

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

Clinical Study Identifier: NCT02630316

Find a site near you

Start Over

Weill Cornell Medical Center

New York, NY United States
  Connect »

The Mount Sinai Hospital

New York, NY United States
  Connect »

NYU Langone Medical Center

New York, NY United States
  Connect »

New York Methodist Hospital

Brooklyn, NY United States
  Connect »

Northwell Health

New Hyde Park, NY United States
  Connect »